Trofinetide clinical trials
Also written NNZ-2566.
How each study uses trofinetide is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- 10 Mar 2023 · DAYBUE · NDA 217026 (FDA, Drugs@FDA)
- European Union
- 20 Aug 2026 · Daybu · EMEA/H/C/006482 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2010 (2)
| Year | Studies |
|---|---|
| 2010 | 2 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 2 |
| 2016 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 12 · Other 0
Neuren Pharmaceuticals Limited (8) · ACADIA Pharmaceuticals Inc. (4)
Studies
Open first, then newest update. How each study uses trofinetide is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- Open-Label Extension Study of Trofinetide for Rett SyndromeTerminatedPhase 3ACADIA Pharmaceuticals Inc.NCT04776746Written as trofinetide
- An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett SyndromeTerminatedPhase 2/3ACADIA Pharmaceuticals Inc.NCT04988867Written as Trofinetide
- Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett SyndromeCompletedPhase 3ACADIA Pharmaceuticals Inc.NCT04279314Written as Trofinetide
- Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)CompletedPhase 3ACADIA Pharmaceuticals Inc.NCT04181723Written as Trofinetide
- A Safety Study of NNZ-2566 in Pediatric Rett SyndromeCompletedPhase 2Neuren Pharmaceuticals LimitedNCT02715115Written as NNZ-2566
- Study of NNZ-2566 in Patients With Traumatic Brain Injury Under EFICCompletedPhase 2Neuren Pharmaceuticals LimitedNCT01366820Written as NNZ-2566
- A Safety Study of NNZ-2566 in Patients With Fragile X SyndromeCompletedPhase 2Neuren Pharmaceuticals LimitedNCT01894958Written as NNZ-2566
- Study of NNZ-2566 in Patients With Traumatic Brain InjuryCompletedPhase 2Neuren Pharmaceuticals LimitedNCT00805818Written as NNZ-2566
- A Safety Study of NNZ-2566 in Patients With Rett SyndromeCompletedPhase 2Neuren Pharmaceuticals LimitedNCT01703533Written as NNZ-2566
- A Safety and Efficacy Study of NNZ-2566 in Patients With Mild Traumatic Brain Injury (mTBI)TerminatedPhase 2Neuren Pharmaceuticals LimitedNCT02100150Written as NNZ-2566
- Safety Study of NNZ-2566 in Healthy Female SubjectsCompletedPhase 1Neuren Pharmaceuticals LimitedNCT00961779Written as NNZ-2566
- Safety Study of NNZ-2566 in Healthy Subjects, Following Oral AdministrationCompletedPhase 1Neuren Pharmaceuticals LimitedNCT01420042Written as NNZ-2566
Codes
What other systems call trofinetide · ClinicalTrials.gg INT001245
- MeSH (NLM) C000656362trofinetideOne source NLM
- UNII (FDA) Z2ME8F52QLTROFINETIDEConfirmed FDA, NLM, Wikidata
- Wikidata Q27294917trofinetideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152757TrofinetideOne source FDA
- DrugBank DB06045One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000656362 | trofinetide | One source NLM |
| UNII (FDA) | Z2ME8F52QL | TROFINETIDE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27294917 | trofinetide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152757 | Trofinetide | One source FDA |
| DrugBank | DB06045 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.